Generic drug industry dynamics

Review of Economics and Statistics

Volumn 87, Issue 1, 2005, Pages 37-49

  Reiffen, David ^a   Ward, Michael R ^b  

^a Office of the Chief Economist   (United States)

^b UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 15944403606     PISSN: 00346535     EISSN: None     Source Type: Journal    
DOI: 10.1162/0034653053327694     Document Type: Article

References (27)

1. American Hospital Formulary Services, Drug Information (Bethesda, MD, 1996).
2. Aronsson, T., M. Bergman, and N. Rudman "The Impact of Generic Drug Competition on Brand Name Market Shares - Evidence from Micro Data," Review of Industrial Organization 19 (2001), 425-435.
3. Berry, S., "Estimation of a Model of Entry in the Airline Industry," Econometrica 60 (1992), 889-917.
4. Berndt, E., L. Bui, D. Reilly, and G. Urban, "Information, Marketing, and Pricing in the U.S. Antiulcer Drug Market," American Economic Review 85 (1995), 100-105.
5. Bhattacharya, J., and W. Vogt, "A Simple Model of Pharmaceutical Price Dynamics," Journal of Law and Economics 46 (2003), 599-626.
6. Bond, R., and D. Lean, Sales, Promotion and Product Differentiation in Two Prescription Markets, (Washington, DC: Staff Report to the Federal Trade Commission, 1977).
7. Bresnahan, T., "Empirical Studies of Industries with Market Power," (pp. 1011-1057), in Richard Schmalensee (Ed.), Handbook of Industrial Organization (Elsevier Science, 1989).
8. Bresnahan, T., and P. Reiss, "Entry and Competition in Concentrated Markets," Journal of Political Economy 91, 977-109 (1991).
9. Caves, R., M. Whinston, and M. Hurwicz, "Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry," Brookings Papers on Economic Activity: Microeconomics (1991), 1-66.
10. Cook, A., How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry (Washington, DC: Congressional Budget Office Study, 1998).
11. Demsetz, H., "Industry Structure, Market Rivalry, and Public Policy," Journal of Law and Economics 16, 1-10 (1973).
12. DiMasi, J., R. Hansen, and H. Grabowski, "Cost of Innovation in the Pharmaceutical Industry," Journal of Health Economics 22, 151-185 (2003).
13. Ellison, G., and S. Ellison, "Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration," MIT working paper (2000).
14. Frank, R., and D. Salkever, "Generic Entry and the Pricing of Pharmaceuticals," Journal of Economics and Management Strategy 6 (1997), 75-90.
15. Gisser, M. "Dynamic Gains and Static Losses in Oligopoly: Evidence from the Beer Industry," Economic Inquiry 37 (1999), 554-575.
16. Gort, M., and S. Klepper, "Time Paths in the Diffusion of Product Innovations," The Economic Journal 92 (1982), 630-653.
17. Grabowski, H., and J. Vernon, "Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act," Journal of Law and Economics 35 (1992), 331-351.
18. Greene, William H., Econometric Analysis, 5th ed. (Upper Saddle River, NJ: Prentice-Hall, 2003).
19. Hausman, Jerry, "Specification Tests in Econometrics," Econometrica 46 (1978), 1251-1272.
20. Jovanovic, B., and G. MacDonald, "The Life Cycle of a Competitive Industry," Journal of Political Economy 102 (1994), 322-347.
21. Klepper, S., and K. Simons, "The Making of an Oligopoly: Survival and Technological Change in the Evolution of the U.S. Tire Industry," Journal of Political Economy 108 (2000), 728-760.
22. Lu, Z., and W. Comanor, "Strategic Pricing and New Pharmaceuticals," this REVIEW, 80 (1998), 108-118.
23. Moulton, B., "Random Group Effects and the Precision of Regression Estimates," Journal of Econometrics 32 (1986), 385-397.
24. Reiffen, D., and M. Ward, "Generic Drug Industry Dynamics," Federal Trade Commission working paper no. 248 (2002).
25. Scott Morton, F., "Barriers to Entry, Brand Advertising, and Generic Entry in the U.S. Pharmaceutical Industry," International Journal of Industrial Organization 18 (2000), 1085-1104.
26. _ "Entry Decisions in the Generic Pharmaceutical Industry," Rand Journal of Economics 30 (1996), 421-440.
27. Wiggins, S., and R. Maness, "Price Competition in Pharmaceuticals: The Case of Anti-infectives," Economic Inquiry 42 (2004), 247-263.